MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318551 | Name: Podofilox
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Podofilox, also known as Podophyllotoxin, is a potent inhibitor of microtubule assembly and DNA topoisomerase II. It is a kind of non-alkaloid toxin lignan extracted from the roots and rhizomes of Podophyllum plant and has shown to inhibit the growth of various carcinoma cells. Podophyllotoxin is a natural product that inhibits the polymerization of tubulin and has served as a prototype for the development of diverse antitumor agents in clinical use.

Chemical Structure

Podofilox
Podofilox
CAS#518-28-5

Theoretical Analysis

MedKoo Cat#: 318551

Name: Podofilox

CAS#: 518-28-5

Chemical Formula: C22H22O8

Exact Mass: 414.1315

Molecular Weight: 414.41

Elemental Analysis: C, 63.76; H, 5.35; O, 30.89

Price and Availability

Size Price Availability Quantity
50mg USD 90.00 Ready to ship
100mg USD 150.00 Ready to ship
250mg USD 250.00 Ready to ship
500mg USD 350.00 Ready to ship
1g USD 550.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Podofilox; Podophyllotoxin; Condylox; Wartec; Condyline; NSC 24818.
IUPAC/Chemical Name
(5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
InChi Key
YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChi Code
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
SMILES Code
COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C21B03B23
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Podofilox (Podophyllotoxin) is a potent inhibitor of microtubule assembly and DNA topoisomerase II.
In vitro activity:
In this study, the inhibition of cell growth and changes in protein expression induced by podophyllotoxin were investigated in human cervical carcinoma HeLa cells. Results demonstrate that Podophyllotoxin inhibits HeLa cell growth and induces apoptosis. By using proteomic techniques, seven proteins were found to be significantly regulated by podophyllotoxin compared to the untreated control; among them, four were down-regulated and three were up-regulated. Reference: Am J Chin Med. 2013;41(1):163-75. https://pubmed.ncbi.nlm.nih.gov/23336514/
In vivo activity:
In this study, the efficacy of a more soluble and less toxic polyamidoamine (PAMAM) dendrimer-conjugated podophyllotoxin (DPODO) was evaluated against chemically induced hepatocellular carcinoma (HCC) in mice. The HCC-induced mice were treated with 10 or 20 mg per kg body weight DPODO. The DENA administration led to HCC development, characterized by anisocytosis, karyomegaly, inflammation and degenerative changes in the liver. The DPODO treatment at 10 mg and 20 mg doses significantly reduced the histopathological changes in liver tissue. The DPODO treatment also significantly lowered the levels of inflammatory markers IL-6 and NF-κB in serum and tissue, respectively. Reference: Toxicol Res (Camb). 2019 May 22;8(4):560-567. https://pubmed.ncbi.nlm.nih.gov/31367338/
Solvent mg/mL mM comments
Solubility
DMSO 15.0 36.20
DMF 15.0 36.20
DMSO:PBS (pH 7.2) (1:3) 0.3 0.60
Ethanol 0.1 0.34
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 414.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. An J, Liu Y, Duo S, Ma X, An L, Yan Y, Ji D, Yan Y, Cheng Q, Su Z. Podofilox suppresses gastric cancer cell proliferation by regulating cell cycle arrest and the c-Myc/ATG10 axis. Exp Ther Med. 2021 Nov;22(5):1203. doi: 10.3892/etm.2021.10637. Epub 2021 Aug 23. PMID: 34584548; PMCID: PMC8422391. 2. Wang B, Chen L, Zhen H, Zhou L, Shi P, Huang Z. Proteomic changes induced by podophyllotoxin in human cervical carcinoma HeLa cells. Am J Chin Med. 2013;41(1):163-75. doi: 10.1142/S0192415X13500122. PMID: 23336514. 3. Sharma S, Mehak, Chhimwal J, Patial V, Sk UH. Dendrimer-conjugated podophyllotoxin suppresses DENA-induced HCC progression by modulation of inflammatory and fibrogenic factors. Toxicol Res (Camb). 2019 May 22;8(4):560-567. doi: 10.1039/c9tx00103d. PMID: 31367338; PMCID: PMC6621132. 4. Choi JY, Cho HJ, Hwang SG, Kim WJ, Kim JI, Um HD, Park JK. Podophyllotoxin acetate enhances γ-ionizing radiation-induced apoptotic cell death by stimulating the ROS/p38/caspase pathway. Biomed Pharmacother. 2015 Mar;70:111-8. doi: 10.1016/j.biopha.2014.12.038. Epub 2015 Jan 12. PMID: 25776488.
In vitro protocol:
1. An J, Liu Y, Duo S, Ma X, An L, Yan Y, Ji D, Yan Y, Cheng Q, Su Z. Podofilox suppresses gastric cancer cell proliferation by regulating cell cycle arrest and the c-Myc/ATG10 axis. Exp Ther Med. 2021 Nov;22(5):1203. doi: 10.3892/etm.2021.10637. Epub 2021 Aug 23. PMID: 34584548; PMCID: PMC8422391. 2. Wang B, Chen L, Zhen H, Zhou L, Shi P, Huang Z. Proteomic changes induced by podophyllotoxin in human cervical carcinoma HeLa cells. Am J Chin Med. 2013;41(1):163-75. doi: 10.1142/S0192415X13500122. PMID: 23336514.
In vivo protocol:
1. Sharma S, Mehak, Chhimwal J, Patial V, Sk UH. Dendrimer-conjugated podophyllotoxin suppresses DENA-induced HCC progression by modulation of inflammatory and fibrogenic factors. Toxicol Res (Camb). 2019 May 22;8(4):560-567. doi: 10.1039/c9tx00103d. PMID: 31367338; PMCID: PMC6621132. 2. Choi JY, Cho HJ, Hwang SG, Kim WJ, Kim JI, Um HD, Park JK. Podophyllotoxin acetate enhances γ-ionizing radiation-induced apoptotic cell death by stimulating the ROS/p38/caspase pathway. Biomed Pharmacother. 2015 Mar;70:111-8. doi: 10.1016/j.biopha.2014.12.038. Epub 2015 Jan 12. PMID: 25776488.
1: Huang M, Zhu X, Wang C, He L, Li L, Wang H, Fan G, Wang Y. PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells. Cell Death Dis. 2024 Aug 22;15(8):610. doi: 10.1038/s41419-024-07009-6. PMID: 39174499; PMCID: PMC11341912. 2: Eltelbanei MA, El-Bassiouny NA, Abdalla MS, Khalaf M, Werida RH. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation. BMC Cancer. 2024 Aug 13;24(1):1002. doi: 10.1186/s12885-024-12694-9. PMID: 39134959; PMCID: PMC11320894. 3: Henter JI, von Bahr Greenwood T. Etoposide Therapy of Cytokine Storm Syndromes. Adv Exp Med Biol. 2024;1448:525-551. doi: 10.1007/978-3-031-59815-9_35. PMID: 39117837. 4: Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, Sevilla I, Benavent M, Alonso-Gordoa T, Custodio A, Anton-Pascual B, Hernando J, Polo E, Castillo-Trujillo OA, Lamas-Paz A, Teijo A, Rodriguez-Gil Y, Soldevilla B, Garcia-Carbonero R. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nat Commun. 2024 Aug 8;15(1):6753. doi: 10.1038/s41467-024-50969-8. PMID: 39117670; PMCID: PMC11310219. 5: Xu D, Chi Y, He HW, Chen CY, Zhou H, Liu X, Xu G. Structural Simplification of Podophyllotoxin: Discovery of γ-Butyrolactone Derivatives as Novel Antiviral Agents for Plant Protection. J Agric Food Chem. 2024 Aug 21;72(33):18423-18433. doi: 10.1021/acs.jafc.4c04312. Epub 2024 Aug 6. PMID: 39106460. 6: Yao X, Wu K, Lu B, Lin F. Neuroendocrine carcinoma of the gallbladder: A case report and literature review. Medicine (Baltimore). 2024 Aug 2;103(31):e39147. doi: 10.1097/MD.0000000000039147. PMID: 39093760; PMCID: PMC11296443. 7: Zhu Z, Li X, Yuan X, Chen X, Lin T, Guo X, Li N. Efficacy and safety of stem cell mobilization with etoposide +cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma. Front Immunol. 2024 Jul 18;15:1439253. doi: 10.3389/fimmu.2024.1439253. PMID: 39091501; PMCID: PMC11291192. 8: Nagavath R, Thupurani MK, Badithapuram V, Manchal R, Vasam CS, Thirukovela NS. Organo NHC catalyzed aqueous synthesis of 4β-isoxazole-podophyllotoxins: in vitro anticancer, caspase activation, tubulin polymerization inhibition and molecular docking studies. RSC Adv. 2024 Jul 26;14(33):23574-23582. doi: 10.1039/d4ra04297b. PMID: 39070249; PMCID: PMC11276401. 9: Julia E, Bachy E. Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP? Lancet Haematol. 2024 Sep;11(9):e634-e636. doi: 10.1016/S2352-3026(24)00207-2. Epub 2024 Jul 24. PMID: 39067466. 10: Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep;11(9):e671-e681. doi: 10.1016/S2352-3026(24)00171-6. Epub 2024 Jul 24. PMID: 39067464. 11: Paczkowski F, Raphael J, Browne C. Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report. Curr Oncol. 2024 Jun 27;31(7):3682-3689. doi: 10.3390/curroncol31070271. PMID: 39057143; PMCID: PMC11276320. 12: Lu LW, Shi XQ, Xu S, Wu D, Wang L, Fu D, Xu ZY. [Diagnosis and treatment of small-cell carcinoma of the prostate: A report of 2 cases]. Zhonghua Nan Ke Xue. 2024 Jan;30(1):40-43. Chinese. PMID: 39046412. 13: Walton A, Powell M, Silva SG, Jin H, Hatch D, Spasojevic I. Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic. Clin J Oncol Nurs. 2024 Jul 19;28(4):380-388. doi: 10.1188/24.CJON.380-388. PMID: 39041693. 14: Hu J, Wang J, Wang Z. The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study. Front Immunol. 2024 Jul 8;15:1415597. doi: 10.3389/fimmu.2024.1415597. PMID: 39040100; PMCID: PMC11260630. 15: Zhang X, Lou X, Qiao H, Jiang Z, Sun H, Shi X, He Z, Sun J, Sun M. Supramolecular self-sensitized dual-drug nanoassemblies potentiating chemo- photodynamic therapy for effective cancer treatment. Int J Pharm. 2024 Sep 5;662:124496. doi: 10.1016/j.ijpharm.2024.124496. Epub 2024 Jul 19. PMID: 39033943. 16: Choderlos de Laclos X, Risbourg S, Brennan B, Bertucci F, Gaspar N, Gelderblom H, Hawkins DS, Janeway K, Juergens H, Kasper B, Krailo MD, Cécile Le Deley M, Marec-Bérard P, McCabe MG, Metzler M, Ranft A, Strauss S, Tabone MD, Windsor R, Dirksen U, Gandemer V. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. Eur J Cancer. 2024 Sep;208:114229. doi: 10.1016/j.ejca.2024.114229. Epub 2024 Jul 15. PMID: 39032218; PMCID: PMC11331277. 17: Su Y, Lai W. Unraveling the Mechanism of the Oxidative C-C Bond Coupling Reaction Catalyzed by Deoxypodophyllotoxin Synthase. Inorg Chem. 2024 Jul 29;63(30):13948-13958. doi: 10.1021/acs.inorgchem.4c01263. Epub 2024 Jul 15. PMID: 39008659. 18: Glynn RA, Hayer KE, Bassing CH. ATM-dependent Phosphorylation of Nemo SQ Motifs Is Dispensable for Nemo-mediated Gene Expression Changes in Response to DNA Double-Strand Breaks. J Immunol. 2024 Sep 1;213(5):628-640. doi: 10.4049/jimmunol.2300139. PMID: 39007641. 19: Darmawan F, Fauzi AR, Pratignyo RB, Kumaladewi P, Rahmadanty AE, Santhony AN, Rinonce HT, Gunadi. Challenges in the diagnosis and treatment of pure non- gestational uterine choriocarcinoma in a child: a case report. J Med Case Rep. 2024 Jul 15;18(1):323. doi: 10.1186/s13256-024-04664-3. PMID: 39004746; PMCID: PMC11247814. 20: Laches R, Hall RJ, Chaffin J, Hahn P. Omission of etoposide in the treatment of haemophagocytic lymphohistiocytosis secondary to primary central nervous system lymphoma with satisfactory response. BMJ Case Rep. 2024 Jul 12;17(7):e258559. doi: 10.1136/bcr-2023-258559. PMID: 39002953.